देश: ताइवान
भाषा: चीनी
स्रोत: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)
DESMOPRESSIN ACETATE
輝凌藥品股份有限公司 台北市中山區松江路111號11樓 (86386138)
H01BA02
錠劑
DESMOPRESSIN ACETATE (6828000210) MG
塑膠瓶裝;;盒裝
製 劑
須由醫師處方使用
FERRING INTERNATIONAL CENTER S.A. CHEMIN DE LA VERGOGNAUSAZ 50, CH-1162 SAINT-PREX, SWITZERLAND CH
desmopressin
中樞尿崩症,原發性夜尿症(限用於7歲以上病患),成人因夜間多尿所導致之夜尿症。
有效日期: 2028/09/11; 英文品名: MINIRIN TABLETS 0.1 MG
2018-05-22
QUALITATIVE AND QUANTITATIVE COMPOSITION MINIRIN ® Tablets 0.1 mg: Each tablet contains desmopressin acetate 0.1 mg equivalent to desmopressin (free base) 0.089 mg. MINIRIN ® Tablets 0.2 mg: Each tablet contains desmopressin acetate 0.2 mg equivalent to desmopressin (free base) 0.178 mg. For a full list of excipients, see section LIST OF EXCIPIENTS. PHARMACEUTICAL FORM Oral Tablet Minirin ® 0.1 mg: White, oval and convex tablets with a single score and marked "0.1" on one side. Minirin ® 0.2 mg: White, round and convex tablets with a single score and marked "0.2" on one side. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. THERAPEUTIC INDICATIONS - Central diabetes insipidus. The use of MINIRIN ® in patients with an established diagnosis will result in a reduction in urinary output with concomitant increase in urine osmolality and decrease in plasma osmolality. This will result in decreased urinary frequency and decreased nocturia. - Primary nocturnal enuresis in children aged 7 years or more. - Symptomatic treatment of nocturia in adults associated with nocturnal polyuria, i.e. nocturnal urine production exceeding bladder capacity. POSOLOGY AND METHOD OF ADMINISTRATION GENERAL Effect of food: Food intake may reduce the intensity and duration of the antidiuretic effect at low doses of desmopressin (see section INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION) In the event of signs or symptoms of water retention and/or hyponatraemia (headache, nausea/vomiting, weight gain, and, in severe cases, convulsions) treatment should be interrupted until the patient has fully recovered. When restarting treatment strict fluid restriction should be enforced (see section SPECIAL WARNINGS AND PRECAUTIONS FOR USE). If adequate clinical effect is not achieved within 4 weeks following appropriate dose titration the medication should be discontinued. INDICATION SPECIFIC _Central diabetes insipidus:_ Dosage is individual in diabetes insipidus but c पूरा दस्तावेज़ पढ़ें